Study guide

16.4 Common Infections and Anti-Infectives

ANCC Family Nurse Practitioner FNP-BC

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 Current Exam Facts 1.2 Eligibility, Application, and Test Day 1.3 Blueprint Weights, TCO Dates, and Study Strategy

2 Assessment Foundations

2.1 Population Health Promotion and Screening 2.2 Comprehensive History and Physical 2.3 Focused History and Physical 2.4 Age-Specific Screening Schedules

3 Function, Risk, and Lifespan Assessment

3.1 Functional Assessment 3.2 Risk Assessment and Social Determinants 3.3 Pediatric Developmental Assessment 3.4 Adolescent, Adult, and Geriatric Assessment

4 Diagnosis Foundations

4.1 Pathogenesis and Pathophysiology 4.2 Diagnostic Test and Procedure Selection 4.3 Interpreting Labs and Imaging 4.4 Normal vs Abnormal Physiologic Change

5 Differential Diagnosis

5.1 Formulating Differential Diagnoses 5.2 Red Flags and Emergency Identification 5.3 Diagnostic Reasoning Traps

6 Prevention and Anticipatory Guidance

6.1 Primary, Secondary, and Tertiary Prevention 6.2 Pediatric and Adolescent Anticipatory Guidance 6.3 Adult and Geriatric Anticipatory Guidance 6.4 Immunization Planning Across the Lifespan

7 Guidelines, Culture, and Evidence

7.1 Crisis, Safety, and End-of-Life Planning 7.2 Clinical Guidelines and Standards of Care 7.3 Culturally and Ethnically Sensitive Practice 7.4 Evidence-Based Research Appraisal

8 Care Plans and Shared Decisions

8.1 Shared Decision-Making 8.2 Multimorbidity and Prioritization 8.3 Referral, Comanagement, and Transitions

9 Pharmacotherapeutics

9.1 Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics 9.2 Interactions, Contraindications, and Monitoring 9.3 Special-Population Prescribing 9.4 High-Alert Medications and Analgesic Safety

10 Cardiovascular Primary Care

10.1 Cardiovascular Diagnosis 10.2 Cardiovascular Pharmacotherapy 10.3 Nonpharmacologic Cardiovascular Management 10.4 Lifespan Cardiovascular Issues

11 Respiratory Primary Care

11.1 Respiratory Diagnosis 11.2 Respiratory Pharmacotherapy 11.3 Lifespan Respiratory Care

12 Endocrine and Metabolic Primary Care

12.1 Diabetes Diagnosis and Monitoring 12.2 Diabetes Pharmacotherapy 12.3 Thyroid and Other Endocrine Disorders 12.4 Obesity and Metabolic Disease

13 Gastrointestinal Primary Care

13.1 Gastrointestinal Diagnosis 13.2 GI Pharmacotherapy and Nutrition 13.3 Lifespan Gastrointestinal Care

14 GU, Renal, and Reproductive Primary Care

14.1 GU and Renal Diagnosis and Management 14.2 Women's Reproductive Health 14.3 Pregnancy and Postpartum Primary Care 14.4 Men's Health and Sexual Function

15 HEENT, Skin, and Musculoskeletal

15.1 HEENT Diagnosis and Management 15.2 Integumentary Diagnosis and Management 15.3 Musculoskeletal Diagnosis 15.4 MSK Procedures and Nonpharmacologic Care

16 Neuro, Psych, Heme, Immune, and Infection

16.1 Neurological Diagnosis and Management 16.2 Psychiatric Diagnosis and Substance Use 16.3 Hematopoietic and Immune Disorders 16.4 Common Infections and Anti-Infectives

17 Clinical Delivery Skills

17.1 Office Procedures and Nonpharmacologic Treatment 17.2 Patient-Specific Education 17.3 Therapeutic Communication 17.4 Comprehensive Documentation

18 Professional Practice

18.1 Legal and Ethical Implications 18.2 Health IT, EHR, and AI Ethics 18.3 Regulatory Guidelines: Reportable Disease and Abuse 18.4 APRN Scope, Standards, and FNP Role

19 Outcome Evaluation

19.1 Ethical and Legal Evaluation Issues 19.2 Pharmacotherapeutic Outcome Monitoring 19.3 Nonpharmacologic Outcome Monitoring 19.4 Clinical Data, PROs, and Treatment Efficacy

20 Follow-Up, Systems, and Exam Strategy

20.1 Follow-Up Intervals and Surveillance 20.2 Treatment Adjustment and Deprescribing 20.3 Resource Management and Care Coordination 20.4 Exam-Day Strategy and TCO Review

16.4 Common Infections and Anti-Infectives

Key Takeaways Explain This Topic AI

Stewardship first: no antibiotic for a viral URI, most acute bronchitis, or early uncomplicated sinusitis inside the viral window.

Treat when the syndrome is bacterial: streptococcal pharyngitis, AOM that meets AAP treat rules, acute cystitis, CAP, and cellulitis — and culture when the result will change the drug.

Early Lyme disease is treated with doxycycline even in young children; the old absolute under-8 doxycycline ban is outdated for short Lyme courses (AAP/CDC).

Influenza and COVID antivirals help when started early in eligible patients. Antibiotics can cause C. difficile — test post-antibiotic watery diarrhea and stop the offending drug.

True IgE penicillin allergy is not the same as a delayed childhood rash or an unknown label. Cephalosporin cross-reactivity is much lower than the old 10% folklore. Measles, TB, gonorrhea, syphilis, HIV, and pertussis are reportable — full regulatory detail is a later chapter.

Last updated: August 2026

The current FNP-BC Test Content Outline lists anti-infective agents as an official drug-agent class. Domain III Planning asks whether the guideline supports a drug at all. Domain IV Implementation asks whether the molecule, the dose, the allergy story, and the culture make sense. Respiratory diagnosis already separated bronchitis from pneumonia (Section 11.1) and HEENT already walked AOM observe-versus-treat and sinusitis day-10 rules (Section 15.1). This section is the antibiotic decision that sits on top of those diagnoses.

Stewardship: the infections that do not get a prescription

Most primary-care respiratory illnesses are viral. Do not prescribe antibiotics for:

Uncomplicated viral upper-respiratory infection (clear or colored mucus, sore throat with cough and rhinorrhea, 3–7 days of cold symptoms)

  • Most acute bronchitis in a well adult with a nonfocal exam (Section 11.1)
  • Early sinusitis still inside the viral window — colored mucus on day 4 is not bacteria (Section 15.1)

Stewardship is not stinginess. It is how you avoid C. difficile , resistant organisms, rashes you will later call “allergies,” and a population that expects a Z-pak for every winter. Give a specific viral diagnosis, a time course (“cough often lasts two to three weeks”), and the return precautions that make observation safe. A rescue plan for true deterioration is allowed. A 14-day “just in case” amoxicillin course is not.

Syndromes you do treat — and when to culture

Group A strep pharyngitis. Test only when viral features are absent (Section 15.1). Treat a positive RADT with penicillin V or amoxicillin for 10 days (or intramuscular benzathine penicillin G if adherence is doubtful). The point is rheumatic-fever prevention , not a shorter sore throat by 16 hours. Macrolides are for true penicillin allergy, not convenience.

Acute otitis media. Use the AAP age, laterality, and severity table from HEENT. When you treat, high-dose amoxicillin is first-line unless the child had recent amoxicillin or has otitis-conjunctivitis (then amoxicillin-clavulanate).

Acute uncomplicated cystitis in a nonpregnant woman is nitrofurantoin (typically 5 days), trimethoprim-sulfamethoxazole for 3 days when local resistance allows, or single-dose fosfomycin. Do not lead with a fluoroquinolone. Do send a urine culture in pregnancy, in men, in pyelonephritis, after relapse or treatment failure, and in children — those are not “same as last time, no culture” visits. Pyelonephritis (fever, flank pain, nausea) is a different drug and a different disposition if the patient cannot keep fluids down.

Outpatient community-acquired pneumonia. Follow current IDSA adult options and local resistance: in many previously healthy outpatients that is high-dose amoxicillin or doxycycline , not automatic azithromycin (Section 11.2). Hypoxia, hypotension, or a frail older adult who cannot manage oral therapy is an emergency-department pneumonia, not a five-day office experiment.

Cellulitis. Nonpurulent spreading erythema is usually streptococcal — cephalexin or another beta-lactam that covers strep. Purulent cellulitis or abscess is Staphylococcus , including MRSA in many communities: drain the abscess (source control is the treatment), and if you add a drug use trimethoprim-sulfamethoxazole or doxycycline according to local susceptibility. A rapidly spreading toxic infection, crepitus, or orbital involvement leaves the clinic.

Culture when the result changes the drug: recurrent or complicated UTI, pyelonephritis, treatment failure, abscess drainage, gonorrhea/chlamydia NAAT on the right site, and a negative RADT in a child that still needs a backup throat culture. Do not culture every viral pharynx “for completeness.”

Syndrome First anti-infective idea Culture?

  • Viral URI / typical bronchitis None No
  • GAS pharyngitis Penicillin or amoxicillin × 10 days RADT ± backup culture in children
  • AOM meeting treat criteria High-dose amoxicillin No routine
  • Uncomplicated cystitis Nitrofurantoin / TMP-SMX / fosfomycin Yes if pregnant, male, failed, or pyelo
  • Outpatient CAP Amoxicillin or doxycycline in many healthy adults Viral testing if it changes care
  • Nonpurulent cellulitis Strep-active beta-lactam If unusual or failing
  • Early Lyme (EM) Doxycycline, including young children Clinical EM; serology not required to start
  • Tick disease: the doxycycline teaching that changed

Erythema migrans — the expanding annular rash of early Lyme disease — is a clinical diagnosis in an endemic area. Do not wait for a serology that is still negative in early disease. First-line treatment is doxycycline for a short course (commonly 10 days for uncomplicated EM in current CDC-style adult teaching; follow the labeled duration you are using).

Here is the update older exam banks get wrong: the old absolute ban on doxycycline in children younger than 8 years is outdated for short Lyme courses. AAP and CDC support doxycycline for early Lyme disease in young children because dental staining risk with a short doxycycline course is not the hazard once taught for longer tetracycline exposures. Teach that sentence. Do not swing to the opposite error and use doxycycline like amoxicillin for every pediatric ear infection. For Rocky Mountain spotted fever and other life-threatening rickettsial disease, doxycycline is first-line at any age and delay is deadly.

Amoxicillin remains an alternative for Lyme in pregnancy when doxycycline is avoided. Neurologic Lyme, carditis, and arthritis are not office doxycycline-and-see-you-in-a-month problems.

Antivirals, C. difficile, reportable teasers, and allergy folklore

Influenza antivirals (oseltamivir is the usual primary-care name) help most when started within 48 hours of symptom onset . Treat high-risk outpatients and anyone sick enough for hospital care even if the clock has run past 48 hours. Do not withhold oseltamivir from a day-three pregnant patient because a handout said “only 48 hours.”

COVID-19 outpatient antivirals are for high-risk people and must start early (nirmatrelvir-ritonavir is time-limited, commonly within 5 days of symptom onset, and is full of CYP3A interactions — you will reconcile the med list). Do not invent a unique 2026 product-by-product algorithm if you are not sure of this year’s preferred sequence. Teach eligibility + early start + interaction check + follow current CDC/NIH outpatient criteria .

Clostridioides difficile is the stewardship bill coming due. Watery diarrhea during or after antibiotics — especially clindamycin, fluoroquinolones, and later-generation cephalosporins — needs a stool test , not another cephalosporin. Stop the offending antibiotic when you can. First-line treatment of nonfulminant C. difficile is oral vancomycin or fidaxomicin , not metronidazole as the modern default. Fulminant disease (shock, ileus, megacolon) is an emergency. Proton-pump inhibitors and repeated antibiotics raise risk; so does older age.

Reportable diseases get a teaser here because Implementation will score them again in the regulatory chapter (18.3). In primary care you should already recognize and report (to the local or state health department, not to a blog): measles , tuberculosis , gonorrhea , syphilis , HIV , and pertussis , among others. You do not need the full legal matrix in this section. You do need to know that a morbilliform rash with cough, coryza, and conjunctivitis, a night-sweat upper-lobe cough, or a laboratory-confirmed STI is not a private lifestyle issue you file and forget.

Allergy is how good stewardship dies. Sort the label:

True IgE: immediate urticaria, angioedema, anaphylaxis, or bronchospasm — take it seriously.

Delayed maculopapular rash days into a childhood course — often not IgE, often challengeable later.

Unknown (“my mother said I was allergic”) — not the same as anaphylaxis.

The folklore that 10% of penicillin-allergic patients react to cephalosporins is outdated . Cross-reactivity is much lower , especially with later-generation cephalosporins that do not share an R1 side chain with the culprit penicillin. If the index reaction was anaphylaxis , avoid the identical side-chain pair and use allergy resources or a different class for the first doses. If the index reaction was a mild delayed rash, a dissimilar cephalosporin is often acceptable and is better medicine than a default fluoroquinolone for every cellulitis. Document what happened, when, and which drug. “Allergy: PCN” without a reaction is an incomplete history.

FNP traps: azithromycin for day-4 sinus pressure; treating EM with “watchful waiting for serology”; refusing doxycycline to a 6-year-old with classic Lyme because of a retired tooth-staining rule; starting Paxlovid on day 9 in a low-risk 22-year-old while missing the day-1 high-risk 78-year-old; treating C. difficile with more clindamycin; and converting every unknown penicillin label into lifelong fluoroquinolones because of 1980s cross-reactivity folklore.

Loading diagram... Anti-infectives: stewardship first, then the named syndrome